Jnana has raised $50m in a series A round backed by Pfizer and AbbVie to continue development of its protein drug discovery platform.
Pharmaceutical companies Pfizer and AbbVie have invested in a $50m series A round for US-based protein drug developer Jnana Therapeutics through respective subsidiaries Pfizer R&D Innovate and AbbVie Ventures.
Venture capital firms Polaris Partners, Avalon Ventures and Versant Ventures also participated in the round, which followed an undisclosed amount of seed funding from Polaris and Avalon.
Jnana is developing a drug discovery platform dedicated to solute carrier (SLC) transporters, proteins that move substances across cellular membranes.
The company believes SLC…
